PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells
Josephine Kahn(Broad Institute), Peter G. Miller(Broad Institute), Alexander J. Silver(Brigham and Women's Hospital), Rob S. Sellar(Broad Institute), Shruti Bhatt(Harvard University), Christopher J. Gibson(Broad Institute), Marie McConkey(Brigham and Women's Hospital), Dylan Adams(Brigham and Women's Hospital), Brenton G. Mar(Broad Institute), Philipp Mertins(Broad Institute), Shaunt Fereshetian(Broad Institute), Karsten Krug(Broad Institute), Haoling Zhu(Harvard University), Anthony Letai(Harvard University), Steven A. Carr(Broad Institute), John G. Doench(Broad Institute), Siddhartha Jaiswal(Broad Institute), Benjamin L. Ebert(Broad Institute)
Cited by 218Open Access
Abstract
Key Points Truncating PPM1D mutations confer chemotherapy resistance, leading to the selective expansion of PPM1D-mutant cells in vitro and in vivo. PPM1D inhibitor treatment reverses the chemotherapy-resistance phenotype and selectively kills PPM1D-mutant cells.
Related Papers
No related papers found
Powered by citation graph analysis